Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY

CASTLE BIOSCIENCES INC

2025-Q2 EPS reported -$0.74 revenue$174,176,000

Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.
TissueCypher test reports nearly doubled to 9,170 (from 4,782); DecisionDx-Melanoma up 4% to 9,981.
Raising FY2025 total revenue guidance to $310-320M from $287-297M, citing strong core test performance.
Net income $4.5M ($0.16 diluted EPS) vs $8.9M ($0.32) YoY; adjusted EBITDA $10.4M vs $21.5M.
FDA Breakthrough Device designation for DecisionDx-Melanoma; closed Previse acquisition and SciBase collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.